{"name":"Lexicon Pharmaceuticals","slug":"lexicon-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":49803000,"revenueGrowth":60.2,"grossMargin":0,"rdSpend":61121000,"netIncome":-50341000,"cash":184987000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Schedule B","genericName":"Schedule B","slug":"schedule-b","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Schedule B","genericName":"Schedule B","slug":"schedule-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbmNRUXZmdjlpZGtkWGNYZ2Q2UUNoTlkxUGNMV2x5Wm55M2F5c3JTa3ZUMWRlQUMwT1FZQ1REOWZKYzFWRUVQUjNfSnl4c1Z3Z3lHR05jMzY2OXRUNTB5UXQ2MGdVN0lyaWlQbDZZYW1rN3ptUnI3TXdTSzJ4WURWNWszcy1NbzEtdU1qbjA4d2pLZWNndk5HUWptN1dhb2hvZmtrTHhJZjdWZDJJM2NScDQxOXJUY3F0dVV3?oc=5","date":"2026-03-11","type":"pipeline","source":"stocktitan.net","summary":"Diabetes drug sotagliflozin cut low-sugar events, across kidney stages - stocktitan.net","headline":"Diabetes drug sotagliflozin cut low-sugar events, across kidney stages","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-05","type":"earnings","source":"The Manila Times","summary":"Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates - The Manila Times","headline":"Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxObjlZTDQyOTJBWFZmem5EMTRPc0p5NnkzVXZKc28xOEM3RE5aQ0RnZk9mSC1KYWpQaC1Zc3RZRmtpM0pEWUhoT1RxV2FjaFh5c2NsYW1SSUU4MzFJWVY2TWJtZy1LMi0tUGo5eXY5cXNjcHhlRXVFSkRGMlJmWmJvWGk3TQ?oc=5","date":"2026-02-19","type":"deal","source":"Seeking Alpha","summary":"Lexicon Pharma spikes after insider buy - Seeking Alpha","headline":"Lexicon Pharma spikes after insider buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOUGhnSkRTX0JIOGU0VkRyV25nREFRRkRhWGxoTjNkYi1ZZmc4SktOVlFIU3JXaDMyNHFmaTY4YWUzNmRFVmg5d3ZjazZVWTE4OW5wZzUwanBYTW9zNEJKWHIwMERkamViMTVLalVRWjFjRkF4VkU1c2djLTFYZDlRY3RObUo0VDFSTU84MlJsalpoQUdIeWZxOWZ2RTR1THlyaDJ3ak1pY1ZreHk3MU5jbUw5YUhPNFljOGNLbkE1VUZoNEtXR1lxS0FuVQ?oc=5","date":"2026-01-30","type":"pipeline","source":"msn.com","summary":"Lexicon Pharmaceuticals prices $94.6M share offering - msn.com","headline":"Lexicon Pharmaceuticals prices $94.6M share offering","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"pipeline","source":"simplywall.st","summary":"Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st","headline":"Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNNms5cmU1a0FMblVWXzBla01Bb3M5QmpXUjZiQUJQLUFCMnM2bWxvbXYwSHNMLTVvenFRTkNOak9QbVJEZE1LdzJhLUVJNUpIUldIMGY2OXZwMWt1dGdSbEg1Qk1tWHhsRE5KbThyZXJiUWJfeEFOam1JREE1Z21nanR2SFk?oc=5","date":"2026-01-21","type":"regulatory","source":"Seeking Alpha","summary":"Lexicon Pharma rises on FDA views on pain drug (LXRX:NASDAQ) - Seeking Alpha","headline":"Lexicon Pharma rises on FDA views on pain drug (LXRX:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQMGJ5RjVGS0lTazJ2YTFkUmVKU3pzVElLVF94cHNXdExtWUZ0aG9NUFBlbXNYM0JjUGlvekVmOWJiNmUxWVA5cFZFS0hleHBfelRkdW1WTGs2SWtwcEQ3SlNNNVA2cFhyY05LSldlQkNIajJEX1M2bVFkVmJyMHNsTnB1UDB6OXBRQkFOZUtMQi1uamNGVmNzbjUxeGM2TXh6NzA4Y0o4OEYtdWhMcldpWndMbnBwUHh1S0xfZnF3?oc=5","date":"2026-01-12","type":"pipeline","source":"stocktitan.net","summary":"Experimental heart, diabetes and pain drugs move ahead at Lexicon - stocktitan.net","headline":"Experimental heart, diabetes and pain drugs move ahead at Lexicon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOeE81aGpKakVILW8yV19NTlhkSjJzY2ZJVWFZMGFhZHdldXZFT05udnhHWEJlV1ZtbVJIZUZBN2V2bzd4WnhTN0FYNzZRUm5OT2dTcGpzYm40YXdYSWJ3bzNUVld4ZWRqN0FUNkdFMmwwWXVBT21LVko3SE9UbGNCWFFHNlBzZG5CMXhmSml6T2F4TmVWamVnOFU3Wi1IaGdlWGh6WVhhbWRxZEJmUWRQcklaZFo1V1BtT0Njd1ptT3Uydw?oc=5","date":"2025-12-03","type":"pipeline","source":"Seeking Alpha","summary":"Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well - Seeking Alpha","headline":"Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-12","type":"pipeline","source":"simplywall.st","summary":"Private equity firms among Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders, saw gain in holdings value after stock jumped 17% last week - simplywall.st","headline":"Private equity firms among Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders, saw gain in holdings valu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPdGJBeU96MEg2dHVQQmFFcXEycnA4LUtpajM5U3hqSkdTdWo1X1lqVkF2QXNPeG9YOHU5VWlUWmFVdXZ5aGc4YTB1SWtoNmlDWDJqVEdMbWh0Y3hvR3ZLTlZEM3k1SXJjRjB2Mmt5OS1yUVI2NlB3Vk5WZFRKNlRiYW1QclFjUFFESklTb0tfQlgxNVAyclhSNWZEeGR1dUhla21sRGxlZTcyQXZwTWdRdDBUa0lMb0YzRDNFanQxM0tESTI4Tkt1ZUxsQXFFY29yclFjc3FTbEF2MkxjWUV3aHRydWl0Nks3VzNSeTl1YlFTeW5sYTAtRVZkcEI0dmU2dEpkamRxT212Smk4d2ppQ25pN3NTMjhHUV9pZkVxRERxLXdKMlBKei1yUGphZFJiWXdQSEN6ckpKRllpWlJoRWFJUUJWc19rUXVwamJHc1VwWmU0?oc=5","date":"2025-06-05","type":"pipeline","source":"Barchart.com","summary":"Diabetic Peripheral Neuropathy Market on Track for Major Expansion by 2034, According to DelveInsight | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma, Glenmark ","headline":"Diabetic Peripheral Neuropathy Market on Track for Major Expansion by 2034, According to DelveInsight | Grünenthal, Aver","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPRnFvWXhjYXpVWTRwREx0N2lWZHE3aldhZnVTd3ExZTlua1Fnd3ozUXdsM0gyZENtLUZsU3dibHRCUHdGNHgtckQ3V3VBQkt4R0ZVSy01cmxWWHdfNFJCRFpWN2cyUlM5enFBc1VlVFpXSXByb0NwcW4tUDBrdDhNenE2X25hS3hwc0phTzcxTVVhdGlGRXRsYXdRVGI4RE5scGNxODYwRW92US0wNjA3VlFKMlhSLWl1akhMYmFnZXJTdU4tNGRv?oc=5","date":"2024-11-22","type":"regulatory","source":"Fierce Pharma","summary":"After FDA setbacks, Lexicon slashes commercial operations in transition back to clinical-stage outfit - Fierce Pharma","headline":"After FDA setbacks, Lexicon slashes commercial operations in transition back to clinical-stage outfit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQRThmcS0wNVdsbUtSX1NKYkdFWHdveXVpWUsxbFBjUEZVQVE0cHFFZTZ3RUN1SmxRZUR1bm5zSms2Rm5VOWVuWU9WTmFEYzd3bHBwLXpLR0d4NFZWTnlubnVUZ2N2T211eHJyRU1wQ3phclNXamJDVmRyeVIxZkxqRl84RjlrM3ZDaldfQ3FKam5GWUdGWWhLS3M4TkN4bmZFNENvYmQ2VnREaUF0bWNxMjI1c2wybmpYeXQ2OVhqMGU0TGUtUE1OdnZVOUU4LUczVTRrdjBYajg?oc=5","date":"2024-10-31","type":"regulatory","source":"Reuters","summary":"FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters","headline":"FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":49803000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":49803000,"period":"2025-12-31"},{"value":31081000,"period":"2024-12-31"},{"value":31081000,"period":"2024-12-31"},{"value":1204000,"period":"2023-12-31"},{"value":1204000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":61121000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-50341000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":184987000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}